MindMed (MNMD): Assessing Valuation After MM120's Breakthrough Results and Phase 3 Advances [Yahoo! Finance]
Mind Medicine (MindMed) Inc. - Common Shares (MNMD)
Company Research
Source: Yahoo! Finance
The company secured FDA Breakthrough Therapy status and promptly launched three Phase 3 trials. See our latest analysis for Mind Medicine (MindMed). MindMed's breakthrough trial results sparked a surge in investor confidence, sending the share price up 15% over the past week and 81% year-to-date. With a 1-year total shareholder return of 107%, momentum is building as late-stage clinical milestones approach. If you're interested in finding more innovative names charting a similar path in the sector, check out the latest opportunities in our See the full list for free. With excitement building around MindMed's clinical progress and analysts projecting a price nearly twice the current level, investors are now left to consider whether the stock is undervalued or if future growth is already priced in. Price-to-Book of 5.6x: Is it justified? MindMed is currently trading at a price-to-book (P/B) ratio of 5.6x, significantly above both its industry and peer group averages, with th
Show less
Read more
Impact Snapshot
Event Time:
MNMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNMD alerts
High impacting Mind Medicine (MindMed) Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
MNMD
News
- MindMed Announces New Employee Inducement GrantsBusiness Wire
- Mind Medicine (MindMed) (NASDAQ:MNMD) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.MarketBeat
- Mind Medicine (MindMed) (NASDAQ:MNMD) had its price target raised by analysts at Canaccord Genuity Group Inc. from $16.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- Mind Medicine (MindMed) (NASDAQ:MNMD) had its price target lowered by analysts at Royal Bank Of Canada from $21.00 to $20.00. They now have an "outperform" rating on the stock.MarketBeat
- Mind Medicine Inc (MNMD) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... [Yahoo! Finance]Yahoo! Finance
MNMD
Earnings
- 11/6/25 - Miss
MNMD
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/6/25 - Form 10-Q
- 11/6/25 - Form 8-K
- MNMD's page on the SEC website